Season of radiotherapy and outcomes of head & neck cancer patients in the MACH-NC & MARCH meta-analyses.
Radiother Oncol
; 190: 110011, 2024 Jan.
Article
em En
| MEDLINE
| ID: mdl-37956890
ABSTRACT
BACKGROUND:
A single institution retrospective study suggested that head and neck squamous cell cancer (HNSCC) patients receiving radiotherapy (RT) during "dark" season (fall/winter) may have better outcomes than those treated during "light" season (spring/summer), possibly secondary to seasonal variations in cell cycle progression. We investigated the impact of season of RT in two large, multi-institutional, prospective datasets of randomized trials.METHODS:
Individual patient data from the MACH-NC and MARCH meta-analyses were analyzed. Dark season was defined as mid-radiotherapy date during fall or winter and light the reverse, using equinoxes to separate the two periods. Primary endpoint was progression-free survival (PFS) and secondary endpoint was locoregional failure (LRF). The effect of season was estimated with a Cox model stratified by trial and adjusted on sex, tumor site, stage, and treatment. Planned sensitivity analyses were performed on patients treated around solstices, who received "complete radiotherapy", patients treated with concomitant radio-chemotherapy and on trials performed in Northern countries.RESULTS:
11320 patients from 33 trials of MARCH and 6276 patients from 29 trials of MACH-NC were included. RT during dark season had no benefit on PFS in the MARCH (hazard ratio[HR] 1.01 [95%CI 0.97;1.05],p=0.72) or MACH-NC dataset (HR1.00 [95%CI 0.94;1.06],p=1.0. No difference in LRF was observed in the MARCH (HR1.00 [95%CI 0.94;1.06,p=0.95) or MACH-NC dataset (HR0.99 [95%CI 0.91; 1.07],p=0.77). Sensitivity analyses showed similar results.CONCLUSION:
Season of RT had no impact on PFS or LRF in two large databases of HNSCC.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias de Cabeça e Pescoço
Limite:
Humans
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article